Suppression of Upper Lip Hair Growth Using Novel Hemp Extract

Suppression of Upper Lip Hair Growth Using Novel Hemp Extract - A Case Series

A clinical case series will be conducted measuring upper lip hair suppression for cosmetic effects in a group of 25 adult women with hirsutism of the upper lip. The study will use a topical phytonutraceutical that contains two ingredients that have been shown to suppress hair growth. The serum contains Narcissus Tazetta Bulb Extract (0.2%) and a hemp-extract (0.15%) known to stimulate cannabinoid one (CB1) receptors.

The subjects will use the serum nightly for 60 days. High-power ProScope photographs will be obtained at the philtrum (above the center of the upper lip) as a landmark. Prior to starting the serum subjects will grow their upper lip hair for seven days. Hair shafts will be counted and graded for thickness and color using a standard methodology. The subjects will then use the serum for 60 days and will not be allowed to use laser, waxing, bleaching or tweezing during the duration of the study. Only shaving will be allowed. At the end of the 60 day course the subjects will grow their lip hair for seven days and the high-power photographs will be repeated at the same location based on landmarks.

An independent board-certified dermatologist will evaluate and grade the pre- and post- serum photographs for cosmetic effects, number and thickness of the hairs.

Study Overview

• Status: Not yet recruiting
• Conditions: Hair Diseases; Hirsutism
• Intervention / Treatment: Drug: Narcissus Tazetta Bulb Extract and Novel Hemp Extract

Detailed Description

Hirsutism is defined as increased bodily and facial hair growth in females presenting in locations where hair is ordinarily minimal or absent. It affects almost 30% of adult females during their lifetime. Current treatments for hirsutism include the use of oral contraceptives or antiandrogens. These drugs and hormones are associated with adverse effects and they may not manifest results if at all for at least 6 months most cannot be used if the female is pregnant, breastfeeding, or trying to become pregnant. Many women find that a multipronged approach that includes direct hair removal (such as plucking, waxing, shaving, depilatories, bleaches and laser), suppression of androgen production with drugs. More recently an effective prescription topical cream, Eflornithine hydrochloride (brand name: Vaniqa) has become available to slow the growth of unwanted facial hair in women. It does not remove hair permanently. Noticeable results take approximately six to eight weeks, and once the cream is discontinued, hair returns to pretreatment levels after approximately eight weeks. Eflornithine cream may cause skin to redden.

Narcissus Tarzetta Bulb Extract 0.02% IBR-Dormin applied topically reduced hair shaft elongation by 34%. The test also showed the hair follicle started the transition from growth to resting phase (telogen). A study of 3.0% topical extract revealed a delay of men's facial hair regrowth after shaving.

Studies of endocannabinoids and phytocannabinoids that stimulate the cannabinoid one (CB1) receptor reveal that topical application inhibited hair shaft elongation and the proliferation of hair matrix keratinocytes, and induced intraepithelial apoptosis and premature hair follicle regression (catagen).

A clinical case series from serial patients with hirsuitism (adult females) at a dermatology clinic will be conducted measuring upper lip hair suppression for cosmetic effects and change in hair shaft count and color. The study will use a topical phytonutraceutical containing Narcissus Tazetta Bulb Extract (0.2%) and a hemp-extract (0.15%) known to stimulate cannabinoid one (CB1) receptors. Based on prior studies the topical will work locally as a locally active topical without systemic absorption.

The 25 subjects will use the serum nightly for 60 days. High-power ProScope photographs will be obtained at the philtrum (above the center of the upper lip) as a landmark. Prior to starting the serum subjects will grow their upper lip hair for seven days. Hair shafts will be counted and graded for thickness and color using a standard methodology. The subjects will then use the serum for 60 days and will not be allowed to use laser, waxing, depilatories, bleaching or tweezing during the duration of the study. Only shaving will be allowed. At the end of the 60-day trial the subjects will grow their lip hair for seven days and the high-power photographs will be repeated at the same location based on landmarks.

An independent board-certified dermatologist will evaluate and grade the pre- and post-treatment photographs for cosmetic effects, number and thickness of the hairs.

• Study Type: Observational
• Enrollment (Estimated): 25

Contacts and Locations

• Study Contact: Name: Gregory L Smith, MD; Phone Number: 4044514045; Email: DrSmith@NeX-Therapeutics.com
• Study Contact Backup: Name: Shannon Powell, TTS; Phone Number: 8132402369; Email: Shannon@NeX-Therapeutics.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Adult women with physician-diagnosed hirsutism presenting to a dermatology clinic.

Description

Inclusion Criteria:

Physician diagnosed upper lip hirsutism Prior use of therapies to treat the upper lip hirsutism No laser, depilation, or waxing within prior 8 weeks -

Exclusion Criteria:

Local infection near or at application site. Local skin irritation or ulceration near or at application site. Inability to be available for entire duration of study and in-person photographs

-

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Standard Topical NIghtly Dose; Treatment group	Drug: Narcissus Tazetta Bulb Extract and Novel Hemp Extract; Topical nightly application of phytonutraceutical

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hair Follicle Number	The change in the number of identifable hair follicles using high-power ProScope	60 days
Hair Follicle Diameter	The change in the hair average hair follicle diameter using high-power ProScope	60 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hair Shaft Color	The change in the darkness of the hair follicles will be measured using high-power ProScope	60 days

Collaborators and Investigators

• Sponsor: Medical Life Care Planners, LLC

Publications and helpful links

General Publications

• Kopera D, Wehr E, Obermayer-Pietsch B. Endocrinology of hirsutism. Int J Trichology. 2010 Jan;2(1):30-5. doi: 10.4103/0974-7753.66910.
• Gupta AK, Talukder M. Cannabinoids for skin diseases and hair regrowth. J Cosmet Dermatol. 2021 Sep;20(9):2703-2711. doi: 10.1111/jocd.14352. Epub 2021 Aug 7.
• Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, Martin KA, Murad MH. Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1258-1264. doi: 10.1210/jc.2017-02052.

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2023
• Primary Completion (Estimated): December 1, 2023
• Study Completion (Estimated): December 1, 2023

Study Registration Dates

• First Submitted: August 15, 2023
• First Submitted That Met QC Criteria: August 15, 2023
• First Posted (Actual): August 21, 2023

Study Record Updates

• Last Update Posted (Actual): August 21, 2023
• Last Update Submitted That Met QC Criteria: August 15, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Narcissus Tarzetta Bulb Extract; Cannabinoid One (CB1) receptor; IBR-Dormin; Hemp-extract
• Additional Relevant MeSH Terms: Skin Diseases; Virilism; Hirsutism; Hair Diseases
• Other Study ID Numbers: Lip Hair Growth Suppression

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No